Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI
Conditions
Prostate NeoplasmSummary
This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
Detailed Description
PRIMARY OBJECTIVE:
I. To study how a variety of technological approaches in MRI can be used to provide improved performance contrast-enhanced MR imaging as used for angiography and perfusion as well as in MR image acquisition without the use of contrast material.
OUTLINE: This is an observational study.
Participants undergo a non-contrast MRI on study and may optionally undergo a second non-contrast MRI on study. Participants may also undergo blood sample collection on study.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Clinical Trials Referral Office
- 855-776-0015
Principal Investigator
- Stephen J. Riederer, PhD
Eligibility Criteria
Inclusion Criteria:
* Adults
Exclusion Criteria:
* Standard exclusion criteria for clinical MRI; e.g. cardiac pacemaker, claustrophobia, an implanted device that has been determined to be MR conditional at 1.5T but not at 3T, anticipated considerable susceptibility artifact from hip prosthesis, etc.
Study Plan
Observational
Participants undergo a non-contrast MRI on study and may optionally undergo a second non-contrast MRI on study. Participants may also undergo blood sample collection on study.
OTHER:
Non-Interventional StudyDescription:
Non-interventional study
Outcome Measures
Primary Outcome Measures
Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion
Timeline
Last Updated
December 13, 2024Start Date
March 18, 2024Today
May 11, 2025Completion Date ( Estimated )
September 30, 2030
Sponsors of this trial
Lead Sponsor
Mayo ClinicCollaborating Sponsors
National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)